Novocure To Test Tumor Treating Fields With Roche Tecentriq In Pancreatic Cancer
- Novocure Ltd (Get Free Alerts for NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (Get Free Alerts for RHHBY) to develop Tumor Treating Fields (TTFields) together with Roche's atezolizumab in metastatic pancreatic ductal adenocarcinoma (mPDAC).
- The phase 2 study was designed to test the safety and efficacy of TTFields together with atezolizumab, gemcitabine, and nab-paclitaxel as a first-line treatment for mPDAC.
- The study will enroll approximately 75 patients with a primary endpoint of disease control rate.
- The secondary endpoints include overall survival, progression-free survival (PFS), one-year survival, objective response rate, PFS at six months, duration of response, and toxicity profile.
- Novocure is the study sponsor, and Roche is providing atezolizumab for the trial.
- Tumor Treating Fields are electric fields that disrupt cancer cell division.
- Last week, the FDA granted breakthrough designation to the NovoTTF-200T System, TTFields, to be delivered together with atezolizumab and bevacizumab for the first-line treatment of patients with unresectable or metastatic liver cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.